<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="11539">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02956720</url>
  </required_header>
  <id_info>
    <org_study_id>DHF21321</org_study_id>
    <nct_id>NCT02956720</nct_id>
  </id_info>
  <brief_title>UltraShape Power in Combination With U-sculpt-n Transducer</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Syneron Candela</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Syneron Candela</source>
  <brief_summary>
    <textblock>
      Prospective, open label, self - controlled, single arm, clinical study to assess the
      performance of the UltraShape Power using the U-Sculpt-N on outer thigh and/or flank for
      circumference reduction versus self-control.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>January 2017</start_date>
  <primary_completion_date type="Anticipated">October 2017</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Outer thigh and/or flank circumference reduction</measure>
    <time_frame>up to 22 week</time_frame>
    <description>To evaluate circumference reduction of outer thigh and/or flank post treatment with UltraShape Power device used with the U-Sculpt-N transducer versus control side.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Treatment-related adverse events</measure>
    <time_frame>up to 22 week</time_frame>
    <description>The frequency and severity of all treatment-related adverse events during and after using the UltraShape Power device used with the U-Sculpt-N transducer.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Circumference Reduction</condition>
  <arm_group>
    <arm_group_label>single arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>UltraShape Power</intervention_name>
    <arm_group_label>single arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject ≥25 and ≤60 years of age at the time of enrollment

          2. BMI≤ 28

          3. Fat thickness of at least 1.5 cm in the outer thigh and/or flank (measured by
             calibrated caliper)

          4. For women of child-bearing potential: negative urine pregnancy test

          5. General good health confirmed by medical history and skin examination of the treated
             area

          6. Subject understands the study requirements and the treatment procedures and provides
             written Informed Consent before any study-specific tests or procedures are performed.

          7. The subject commits to return for the scheduled post-operative follow-up visits at
             the clinic Willingness to refrain from a change in diet/ exercise/medication regimen
             for the entire course of the study

        Exclusion Criteria:

          1. History of un-balanced hypertension, ischemic heart disease, valvular heart disease,
             congestive heart failure, pacemaker/defibrillator

          2. Current hyperlipidemia, diabetes mellitus, hepatitis, liver disease, HIV positive
             status, blood coagulopathy or excessive bleeding, autoimmune or connective tissue
             disease

          3. Having a permanent implant in the treated area, such as metal plates, or an injected
             chemical substance such as silicone

          4. Previous liposuction in the treatment areas within 12 months

          5. History of skin disease in the treatment area, known tendency to form keloids or poor
             wound healing

          6. Abnormal kidney, liver or coagulation functions, abnormal lipid profile or blood
             count within the last 3 months

          7. Childbirth within the last 12 months or women who are breastfeeding a child

          8. Any acute or chronic condition which, in the opinion of the Investigator, could
             interfere with the conduct of the study

          9. Subjects with poor skin quality (i.e., laxity) and/or amorphic fat deposits at the
             target for treatment areas

         10. Unstable weight within the last 6 months (i.e., more than ± 3% weight change in the
             prior 6 months)

         11. Participation in another clinical study within the last 6 months

         12. Previous body contouring treatments within the last 12months in the areas to be
             treated
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Ketty Shkolnik, Ph.D.</last_name>
    <phone>+972-73-2442268</phone>
    <email>kettys@syneron-candela.com</email>
  </overall_contact>
  <verification_date>November 2016</verification_date>
  <lastchanged_date>November 3, 2016</lastchanged_date>
  <firstreceived_date>October 30, 2016</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Syneron Candela</investigator_affiliation>
    <investigator_full_name>Ronen Glesinger</investigator_full_name>
    <investigator_title>Principal investigator</investigator_title>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
